Eleni F.
- Country
- Greece
- Department
- Department of Medical Oncology
Research Overview
- A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Data & Insights
Has run more than one trial at 411 of 635 partner sites.
Specializations
Oncology Focus
This investigator specializes in treating head and neck squamous cell carcinoma (HNSCC), with particular emphasis on managing both first-line and previously treated cases.
- Metastatic and recurrent HNSCC
- PD-L1 positive tumors
- Advanced stage cancer management
The investigator's work encompasses treating patients with incurable metastatic conditions.
Therapeutic Expertise
The investigator's therapeutic focus includes novel treatment approaches combining immunotherapy with targeted therapies for head and neck cancer.
- Combination therapy approaches
- Immunotherapy integration
- Treatment-resistant cases
Their work involves evaluating innovative therapeutic strategies for both treatment-naive and previously treated patients.
Clinical Assessment
The investigator utilizes advanced clinical assessment methodologies including RECIST criteria for tumor response evaluation.
- Overall survival assessment
- Response rate evaluation
- Biomarker analysis
Their expertise includes comprehensive evaluation of treatment outcomes in advanced cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.